Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06820723 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 5 months later Mar 2027 → Sep 2028
See other at-risk trials from Ohio State University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Mar 2027 to Sep 2028v4 Show 4 more changesShow less
    • Recruitment opened
    • Start date: Nov 2025 to Aug 1, 2026
    • Study completion pushed from Nov 2027 to Nov 2028
    • Site details revised
  2. Start date: Sep 2025 to Nov 2025
    • Secondary endpoints revised (5)
    • Publications: details revised at 8 of 8 entries
    v3
  3. Start date: Mar 2025 to Sep 2025
    • Secondary endpoints: details revised at 3 of 5 entries
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ohio State University
253 trials monitored
See 12 trials at risk
Anxiety
3,263 trials monitored
See 159 trials at risk
Depression
3,055 trials monitored
See 173 trials at risk
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Trial Details
NCT Number NCT06820723
Lead Sponsor Ohio State University
Conditions
(from sponsor)		 Depression, Anxiety, Major Depressive Disorder
Related terms Anxiety Disorders, Depression, Major Depressive Disorder
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov